Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Inventory (2016 - 2025)

Historic Inventory for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to $8.3 million.

  • UroGen Pharma's Inventory rose 983.67% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 983.67%. This contributed to the annual value of $9.2 million for FY2024, which is 6264.76% up from last year.
  • Latest data reveals that UroGen Pharma reported Inventory of $8.3 million as of Q3 2025, which was up 983.67% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Inventory registered a high of $9.2 million during Q4 2024, and its lowest value of $3.3 million during Q1 2021.
  • In the last 5 years, UroGen Pharma's Inventory had a median value of $5.0 million in 2022 and averaged $5.8 million.
  • In the last 5 years, UroGen Pharma's Inventory skyrocketed by 20408.89% in 2021 and then crashed by 1049.25% in 2022.
  • UroGen Pharma's Inventory (Quarter) stood at $4.8 million in 2021, then fell by 10.49% to $4.3 million in 2022, then surged by 31.17% to $5.7 million in 2023, then skyrocketed by 62.65% to $9.2 million in 2024, then decreased by 9.6% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $7.1 million for Q2 2025, and $7.6 million during Q1 2025.